Michele A. Sharr

513 total citations
13 papers, 288 citations indexed

About

Michele A. Sharr is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Michele A. Sharr has authored 13 papers receiving a total of 288 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Cancer Research and 8 papers in Molecular Biology. Recurrent topics in Michele A. Sharr's work include Peptidase Inhibition and Analysis (9 papers), Protease and Inhibitor Mechanisms (9 papers) and Signaling Pathways in Disease (4 papers). Michele A. Sharr is often cited by papers focused on Peptidase Inhibition and Analysis (9 papers), Protease and Inhibitor Mechanisms (9 papers) and Signaling Pathways in Disease (4 papers). Michele A. Sharr collaborates with scholars based in United States, Canada and Switzerland. Michele A. Sharr's co-authors include John F. DiJoseph, Loran M. Killar, Jerauld S. Skotnicki, Jeremy I. Levin, Amy Sung, Rebecca Cowling, Catherine Roth, Guixian Jin, Thomas S. Walter and Suren N. Sehgal and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Medicinal Chemistry and Transplantation.

In The Last Decade

Michele A. Sharr

13 papers receiving 274 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michele A. Sharr United States	11	147	140	139	70	34	13	288
J.S. Skotnicki United States	6	102 0.7×	148 1.1×	137 1.0×	56 0.8×	23 0.7×	8	311
Shintaro Koga Japan	4	92 0.6×	209 1.5×	342 2.5×	26 0.4×	11 0.3×	4	386
Svetlana Paskaš Serbia	11	58 0.4×	66 0.5×	88 0.6×	19 0.3×	25 0.7×	21	290
Lipeng Dai United States	7	56 0.4×	116 0.8×	227 1.6×	41 0.6×	55 1.6×	8	329
M.G. Schlieman United States	5	91 0.6×	226 1.6×	302 2.2×	19 0.3×	28 0.8×	7	426
Minhao Huang China	10	22 0.1×	82 0.6×	197 1.4×	121 1.7×	18 0.5×	19	337
Nahee Park South Korea	11	51 0.3×	146 1.0×	186 1.3×	24 0.3×	12 0.4×	15	347
Erica Reifenberg United States	6	69 0.5×	62 0.4×	111 0.8×	89 1.3×	4 0.1×	7	228
Daliya Banerjee United States	7	45 0.3×	65 0.5×	134 1.0×	22 0.3×	11 0.3×	11	315
Jau‐Chen Lin Taiwan	9	40 0.3×	108 0.8×	131 0.9×	28 0.4×	4 0.1×	17	331

Countries citing papers authored by Michele A. Sharr

Since Specialization

Citations

This map shows the geographic impact of Michele A. Sharr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michele A. Sharr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michele A. Sharr more than expected).

Fields of papers citing papers by Michele A. Sharr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michele A. Sharr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michele A. Sharr. The network helps show where Michele A. Sharr may publish in the future.

Co-authorship network of co-authors of Michele A. Sharr

This figure shows the co-authorship network connecting the top 25 collaborators of Michele A. Sharr. A scholar is included among the top collaborators of Michele A. Sharr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michele A. Sharr. Michele A. Sharr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Porter, David L., Norbert Frey, Alison W. Loren, et al.. (2013). A phase II, dose-optimization trial of autologous T cells genetically engineered to express anti-CD19 chimeric antigen receptor (CART-19) in patients with relapsed or refractory (r/r) CD19+ chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 31(15_suppl). TPS7132–TPS7132. 2 indexed citations

Esser, Ronald E., et al.. (2005). Pharmacodynamic behaviour of the selective cyclooxygenase-2 inhibitor lumiracoxib in the lipopolysaccharide-stimulated rat air pouch model. European Journal of Pharmaceutical Sciences. 25(1). 25–30. 11 indexed citations

Zask, Arie, Ying Gu, J. Donald Albright, et al.. (2003). Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors. Bioorganic & Medicinal Chemistry Letters. 13(8). 1487–1490. 26 indexed citations

Grosu, G, Baihua Hu, John W. Ellingboe, et al.. (2003). Synthesis and Structure−Activity Relationship of α-Sulfonylhydroxamic Acids as Novel, Orally Active Matrix Metalloproteinase Inhibitors for the Treatment of Osteoarthritis. Journal of Medicinal Chemistry. 46(12). 2361–2375. 47 indexed citations

Nelson, Frances C., Efren Delos Santos, Jeremy I. Levin, et al.. (2002). Benzodiazepine inhibitors of the MMPs and TACE. Bioorganic & Medicinal Chemistry Letters. 12(20). 2867–2870. 22 indexed citations

Levin, Jeremy I., Frances C. Nelson, John F. DiJoseph, et al.. (2001). The discovery of anthranilic acid-based mmp inhibitors. Part 3: incorporation of basic amines. Bioorganic & Medicinal Chemistry Letters. 11(22). 2975–2978. 30 indexed citations

Levin, Jeremy I., Yansong Gu, Frances C. Nelson, et al.. (2001). Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases. Bioorganic & Medicinal Chemistry Letters. 11(2). 239–242. 16 indexed citations

Levin, Jeremy I., John F. DiJoseph, Loran M. Killar, et al.. (2001). The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position. Bioorganic & Medicinal Chemistry Letters. 11(2). 235–238. 36 indexed citations

Harris, David C.H., Reza Mortezaei, Lihong Shi, et al.. (1998). Malonyl α-mercaptoketones and α-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 8(10). 1157–1162. 19 indexed citations

10.

Levin, Jeremy I., John F. DiJoseph, Loran M. Killar, et al.. (1998). The synthesis and biological activity of a novel series of diazepine MMP inhibitors. Bioorganic & Medicinal Chemistry Letters. 8(19). 2657–2662. 27 indexed citations

11.

Levin, Jeremy I., John F. DiJoseph, Loran M. Killar, et al.. (1998). The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases. Bioorganic & Medicinal Chemistry Letters. 8(10). 1163–1168. 12 indexed citations

12.

DiJoseph, John F. & Michele A. Sharr. (1998). Dialysis tubing implant assay in the rat: A novel in vivo method for identifying inhibitors of matrix metalloproteinases. Drug Development Research. 43(4). 200–205. 7 indexed citations

13.

DiJoseph, John F., et al.. (1996). THERAPEUTIC BLOOD LEVELS OF SIROLIMUS (RAPAMYCIN) IN THE ALLOGRAFTED RAT. Transplantation. 62(8). 1109–1112. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact